Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) BTC-USD
67,890.10 +1,819.27 (+2.75%) CMC Crypto 200
1,373.55 +42.95 (+3.23%)
Tilray Brands, Inc. (TLRY.TO)
| Previous close | 2.4500 |
| Open | 2.4800 |
| Bid | 2.5300 x N/A |
| Ask | 2.5400 x N/A |
| Day's range | 2.4800 - 2.5400 |
| 52-week range | 2.1600 - 4.6400 |
| Volume | |
| Avg. volume | 1,357,290 |
| Market cap | 2.105B |
| Beta (5Y monthly) | 2.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6100 |
| Earnings date | 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksTilray Brands (TLRY) Lined Up for Q4 Earnings: What Awaits?
Tilray's (TLRY) product innovation, spanning medical cannabis formats, THC-infused beverages and pharmaceutical-grade medicines, enhances its ability to capture new market segments globally.
GlobeNewswireTilray Medical Granted Approval to Introduce Third Medical Cannabis Product in Portugal
Tilray's Solução Oral THC10:CBD10 Medical Cannabis Extract is Now Approved for Medical Use in PortugalCANTANHEDE, Portugal, July 24, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global leader in cannabis research, cultivation, production, and distribution, today announced another milestone achievement in medical cannabis in Europe. Following the successful approval of Tilray Medical whole flower THC 18, and approval for the first cannabis extract in Portug
ZacksTilray Brands, Inc. (TLRY) Suffers a Larger Drop Than the General Market: Key Insights
Tilray Brands, Inc. (TLRY) closed at $1.89 in the latest trading session, marking a -1.56% move from the prior day.
